Circulating Tumor DNA: A Biomarker for Adjuvant Treatment Response in Stage III Colon Cancer
Keywords:
Stage III colon cancer, ctDNA, ALU-247, Adjuvant chemotherapy responseAbstract
In this prospective work, our purpose was to evaluate the impact of circulating tumor DNA (ctDNA) analyses before, during and after adjuvant chemotherapy in completely resected stage III colon cancer patients, particularly in terms of disease-free survival (DFS). Additionally, we aimed to estimate the efficacy of adjuvant chemotherapy in decreasing ctDNA levels in the plasma. From January 2023 to December 2023, 77 patients with stage III colon cancer underwent complete surgical resection, were included in this study. These patients had undergone upfront resection of their primary tumors. All received adjuvant chemotherapy (CAPEOX or FOLFOX regimen) for six-month period. The median followup was 21 months from date of primary surgery. After six months of treatment, ctDNA levels were significantly associated with two-year DFS. Patients with low ctDNA levels exhibited better DFS compared to those with moderate ctDNA levels, who in turn had better DFS than patients with high-level ctDNA. Findings confirm the benefit of adjuvant chemotherapy in eradicating residual tumor cells responsible for tumor recurrence or metastasis.
Downloads
References
Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros M, Znaor A, Soerjomataram I, and Bray, F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 42(1):1-0 (2024).
West, N. P., Hohenberger, W., Weber, K., Perrakis, A., Finan, P. J., and Quirke, P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. Journal of Clinical Oncology, 28(2), 272-278 (2010). DOI: 10.1200/JCO.2009.24.1448
André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., Banzi, M,, Maartense, E., Shmueli, E., Carlsson, G. U., Scheithauer, W., Papamichael, D., Möehler, M., Landolfi, S., Demetter, P., Colote, S., Tournigand, C., Louvet, C., Duval, A., Fléjou, J. F. and de Gramont, A., Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. Journal of Clinical Oncology, 33(35), 4176–4187 (2015). DOI: 10.1200/JCO.2015.63.4238.
Schmoll, H. J., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Hoersch, S., Rittweger, K., and Haller, D. G., Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results of the NO16968 randomized controlled phase III trial. Journal of Clinical Oncology, 33(32), 3733-3740 (2015). DOI: 10.1200/JCO.2015.60.9107
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., Martinelli, E., and Arnold, D., Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 31(10), 1291–1305 (2020). DOI: 10.1016/j.annonc.2020.06.022
Arakawa, S., Ozawa, S., Ando, T., Takeuchi, H., Kitagawa, Y., Kawase, J., Oshima, H., Nagata, H., Atsuta, K., Yoshida, R., Kawabe, N., Umemoto, S., Morise, Z., and Horiguchi, A.,.Highly sensitive diagnostic method for colorectal cancer using the ratio of free DNA fragments in serum. Fujita Medical Journal, 5(1), 14–20 (2019). DOI: 10.20407/fmj.2017-025
Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., and Oxnard, G. R., Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA: A Cancer Journal for Clinicians, 71(2), 176–190 (2021). DOI: 10.3322/caac.21650
Fawzy, A., Sweify, K. M., El-Fayoumy, H. M., and Nofal, N., Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. Journal of the Egyptian National Cancer Institute, 28(4), 235–242. (2016). DOI: 10.1016/j.jnci.2016.08.003.
Parikh, A. R., Van Seventer, E. E., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K., Fish, M. G., Fosbenner, K. D., Miao, B., Phillips, S., Carmichael, J. H., Sharma, N., Jarnagin, J., Baiev, I., Shah, Y. S., Fetter, I. J., Shahzade, H. A., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Dubois, J. S., Franses, J. W., Giantonio, B. J., Goyal, L., Klempner, S. J., Nipp, R. D., Roeland, E. J., Ryan, D. P., Weekes, C. D., Wo, J. Y., Hong, T. S., Bordeianou, L., Ferrone, C. R., Qadan, M., Kunitake, H., Berger, D., Ricciardi, R., Cusack, J. C., Raymond, V. M., Talasaz, A., Boland, G. M., and Corcoran, R. B., Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. (2021) Oct 15;27(20):5586-5594. doi: 10.1158/1078-0432.CCR-21-0410. Epub 2021 Apr 29. PMID: 33926918; PMCID: PMC8530842.
Kotani, D., Oki, E., Nakamura, Y., Yukami, H., Mishima, S., Bando, H., Shirasu, H., Yamazaki, K., Watanabe, J., Kotaka, M., Hirata, K., Akazawa, N., Kataoka, K., Sharma, S., Aushev, V. N., Aleshin, A., Misumi, T., Taniguchi, H., Takemasa, I., Kato, T., Mori, M., and Yoshino, T. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nature Medicine, 29(1), 127-134 (2023). DOI: 10.1038/s41591-022-02115-4
Diergaarde B., Young G., Hall D. W., Mazloom A., Costa G. L., Subramaniam S., Palomares, M. R., Garces, J., Baehner, F. L., and Schoen R. E., Circulating Tumor DNA as a Marker of Recurrence Risk in Stage III Colorectal Cancer: The α-CORRECT Study. Journal of surgical oncology, (2025). 10.1002/jso.27989. doi:10.1002/jso.27989. DOI: 10.1002/jso.27989
Malla, M., Loree, J. M., Kasi, P. M., and Parikh, A. R., Using circulating tumor DNA in colorectal cancer: Current and evolving practices. Journal of Clinical Oncology, 40(24), 2846-2857 (2022). DOI: 10.1200/JCO.21.02615
Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., Lee, B., Cho, J. H., Faragher, I., Jones, I. T., Ptak, J., Schaeffer, M. J., Silliman, N., Dobbyn, L., Li, L., Tomasetti, C., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., and Gibbs, P., Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncology, 5(12), 1710-1717 (2019). DOI: 10.1001/jamaoncol.2019.3616
Henriksen, T. V., Tarazona, N., Frydendahl, A., Reinert, T., Gimeno-Valiente, F., Carbonell-Asins, J. A., Sharma, S., Renner, D., Hafez, D., Roda, D., Huerta, M., Roselló, S., Madsen, A. H., Løve, U. S., Andersen, P. V., Thorlacius-Ussing, O., Iversen, L. H., Gotschalck, K. A., Sethi, H., Aleshin, A., Cervantes, A., and Andersen, C. L., Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clinical Cancer Research, 28(3), 507-517 (2022). DOI: 10.1158/1078-0432.CCR-21-2404
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
